www.beigene.com
www.brukinsa.com/hcp

Contact Information:

Amy Modean (MN)
651-260-1373
amy.modean@beigene.com

Michele Hayes (ND & SD)
612-518-9167
Michele.hayes@beigene.com

Chris Walton (WI)
414-447-2591
Chris.walton@beigene.com

Virtual Exhibit Hall Home

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,000+ employees in the U.S., China, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA^® (zanubrutinib) in the U.S., and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.

Dosing Administration Guide 

myBeiGene HCP Brochure